Kura Oncology (NASDAQ:KURA) Hits New 1-Year Low – Here’s What Happened

Kura Oncology, Inc. (NASDAQ:KURA) hit a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $9.34 and last traded at $9.34, with a volume of 686302 shares changing hands. The stock had previously closed at $9.74.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on KURA shares. Jefferies Financial Group reduced their price target on shares of Kura Oncology from $32.00 to $28.00 and set a “buy” rating for the company in a research report on Thursday, November 21st. Lifesci Capital upgraded Kura Oncology to a “strong-buy” rating in a research note on Tuesday, October 22nd. HC Wainwright raised their target price on Kura Oncology from $32.00 to $37.00 and gave the company a “buy” rating in a research report on Thursday, November 21st. StockNews.com cut Kura Oncology from a “hold” rating to a “sell” rating in a research report on Wednesday, November 20th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Kura Oncology in a research note on Monday, December 9th. One analyst has rated the stock with a sell rating, one has issued a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $29.38.

Kura Oncology Price Performance

The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. The stock’s 50-day moving average is $14.85 and its two-hundred day moving average is $18.37. The stock has a market cap of $709.21 million, a PE ratio of -3.86 and a beta of 0.75.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. nVerses Capital LLC purchased a new stake in Kura Oncology during the 3rd quarter worth about $25,000. Point72 DIFC Ltd acquired a new stake in Kura Oncology in the third quarter valued at approximately $146,000. Quarry LP acquired a new stake in Kura Oncology in the second quarter valued at approximately $196,000. Erste Asset Management GmbH purchased a new position in Kura Oncology in the third quarter worth approximately $215,000. Finally, Bellevue Group AG grew its holdings in Kura Oncology by 36.0% during the 3rd quarter. Bellevue Group AG now owns 13,600 shares of the company’s stock worth $266,000 after acquiring an additional 3,600 shares in the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.